Topic: Biomarkers

AR-V7 Predicts Response in CRPC

Raoul S. Concepcion, MD, FACS, emphasizes the need for more effective biomarkers when determining adequate treatment for patients with castrate-resistant prostate cancer (CRPC). Concurrently, he compares the findings of studies exploring various options, including the AR-V7 splice variant.

Read More

Genomic Markers and DNA Sequencing Testing

Daniel W. Lin, MD, reviews novel and emerging biomarkers across the spectrum of prostate cancer. He then explains an emerging model of prostate cancer treatment with genomic markers and DNA sequencing, discussing newly-identified precision targets and their therapeutic decision-making utility.

Read More
Loading

Join the GRU Community

- Why Join? -